Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Alzheimer's disease (AD) is the most common neurodegenerative disease, with
characteristic extracellular amyloid-β (Aβ) deposition and intracellular accumulation of …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Alzheimer's disease (AD) is the consequence of neuronal death and brain atrophy
associated with the aggregation of protein tau into fibrils. Thus disaggregation of tau fibrils …

Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …